Liver Diseases  >>  erlotinib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
erlotinib / Generic mfg.
NCT00532441: Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

Terminated
2
25
US
Erlotinib, Docetaxel
Gabi Chiorean, MD, Sanofi, OSI Pharmaceuticals
Hepatocellular Carcinoma
08/10
08/10
NCT00605722: A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

Completed
2
51
RoW
bevacizumab (Avastin), erlotinib (Tarceva)
Hoffmann-La Roche
Liver Cancer
09/10
09/10
NCT00791544: Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Terminated
1/2
13
Europe
AVE1642, sorafenib, Nevaxar, erlotinib, Tarceva
Sanofi
Liver Carcinoma
11/09
11/09

Download Options